The Oncology Institute, Inc. TOI R2K

Healthcare · Medical Care Facilities · United States

The Oncology Institute, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services. It also manages clinical trials and palliative care programs; operates combined community clinics and infusion suites; and operates a specialty pharmacy that includes both in-office and mail-order dispensing for complementary oral and self-injectable medications taken by patients concurrent with their in-office cancer therapies. It serves adult and senior cancer patients. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.

Market & Price

Market Cap

$468.92M

Current Price

$4.69

High / Low (52W)

$4.75 / $2.05

Beta

0.36

Valuation

Stock P/E

Industry PE

23.65

Forward P/E

PEG Ratio

Book Value

$-0.16

Price to Book

-29.50

P/S

0.86

EV/EBITDA

-20.98

Dividend Yield

Profitability & Returns

ROCE

-52.79%

ROE

ROA

-12.30%

Profit Margin

-7.97%

Op Margin

-4.42%

EPS (Latest Qtr)

$-0.02

EPS (TTM)

$-0.35

Balance Sheet & Liquidity

Debt/Equity

Quick Ratio

1.13

Current Ratio

1.47

Debt

$104.91M

Total Assets

$164.66M

Current Assets

$112.75M

Working Capital

$41.78M

Ownership

Promoter Holding

18.16%

Chg in Prom Hold

FII / Inst Holding

46.09%

Chg in FII Hold

Financial Snapshot

Enterprise Value

$543.55M

Total Revenue (TTM)

$545.76M

EBITDA

$-25.91M

Free Cash Flow

$-15.31M

Operating Cash Flow

$-21.81M

Shares Outstanding

99.98M

Gross Margin

15.12%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

25.81%

Profit 5Y

-13,324.12%

Revenue (YoY)

41.20%

Earnings (YoY)

PROS

Compounding revenue at 25.8% over 5 years.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Earnings shrank at -13324.1% CAGR over 5 years.
RSI at 77 suggests overbought conditions.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	TOI The Oncology Institute, Inc. R2K	4.69	-	$468.92M	-	-52.79%	-	25.81%	-13,324.12%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	48.58M	49.84M	52.27M	55.16M	60.92M	64.98M	76.19M	80.22M	82.03M	94.67M	98.58M	-	-	104.41M	119.80M	136.56M	141.96M	147.44M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	87.16M	102.30M	117.64M	119.19M	124.13M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	17.25M	17.50M	18.92M	22.77M	23.32M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	27.16M	28.71M	26.97M	29.67M	29.83M
Operating Income	-2.30K	-87.77K	-194.56K	-198.48K	-1.75M	-1.12M	-2.16M	-18.47M	-18.30M	-20.10M	-32.87M	-14.94M	-13.93M	-17.97M	-16.36M	-	-	-9.91M	-11.21M	-8.05M	-6.91M	-6.51M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-12.23M	-13.46M	-12.86M	-3.96M	1.06M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5.57M	1.87M	1.92M	1.92M	1.93M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-19.59M	-17.14M	-16.50M	-7.51M	-2.49M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-131.00K	0	0	0
Net Income	-2.30K	-776.84K	-2.62M	-2.42M	-996.00K	3.21M	-2.98M	19.29M	-5.45M	-2.67M	-30.00M	-16.90M	-17.42M	-19.89M	-15.48M	-	-	-19.59M	-17.01M	-16.50M	-7.51M	-2.49M
Diluted EPS	-	-	-	-	-0.02	0.05	-0.05	0.21	-0.06	-0.17	-0.33	-0.19	-0.19	-0.22	-0.17	-	-	-0.21	-0.15	-0.14	-0.06	-0.02

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	187.51M	-	252.48M	324.24M	393.41M	502.73M
Cost of Revenue	-	-	200.39M	264.67M	339.42M	426.29M
Gross Profit	-	-	52.09M	59.57M	54.00M	76.44M
Operating Expenses	-	-	124.10M	119.72M	114.11M	112.52M
Operating Income	-8.20M	-	-72.01M	-60.15M	-60.12M	-36.08M
EBITDA	-	-	8.40M	-70.45M	-50.88M	-42.52M
Interest Expense	-	-	4.08M	6.78M	7.50M	11.28M
Pretax Income	-	-	-91.00K	-83.10M	-64.66M	-60.74M
Tax Provision	-	-	-243.00K	-36.00K	0	-131.00K
Net Income	-14.32M	-	152.00K	-83.07M	-64.66M	-60.61M
Diluted EPS	-0.24	-0.16	-0.20	-0.92	-0.71	-

Compounded Sales Growth

5 Years:	25.81%
1 Year:	41.20%

Compounded Profit Growth

5 Years:	-13,324.12%
1 Year:	-

Stock Price Performance

1 Year:	+47.02%
6 Months:	+48.42%
3 Months:	+62.28%
1 Month:	+26.42%

Balance Sheet (Annual)

Figures in USD.

Metric	Oct 2019	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	50.00K	65.69M	-	261.67M	209.24M	172.72M	164.66M
Current Assets	-	-	-	-	130.42M	143.49M	112.42M	112.75M
Cash & Equivalents	-	-	900.00K	-	14.01M	33.49M	49.67M	33.56M
Inventory	-	-	-	-	9.26M	13.68M	10.04M	16.88M
Receivables	-	-	-	-	39.82M	42.36M	48.34M	59.00M
Total Liabilities	-	27.30K	37.59M	-	138.49M	152.22M	169.13M	180.38M
Current Liabilities	-	27.30K	28.61M	-	29.72M	34.79M	52.22M	70.96M
Long Term Debt	-	-	6.56M	-	80.62M	86.83M	93.13M	77.40M
Total Debt	-	-	-	-	108.18M	119.67M	123.15M	103.69M
Total Equity	0	42.22M	28.10M	-	123.17M	57.02M	3.59M	-15.72M
Shares Outstanding	-	-	-	-	73.27M	75.88M	77.47M	100.60M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	508.00K	-	-61.76M	-36.31M	-26.54M	-24.59M
Investing Cash Flow	-8.84M	-	-131.61M	62.64M	46.21M	-3.07M
Financing Cash Flow	11.89M	-	92.21M	-6.85M	-3.49M	11.56M
Capital Expenditure	-1.19M	-	-5.53M	-4.57M	-3.79M	-3.20M
Free Cash Flow	-686.00K	-	-67.28M	-40.88M	-30.33M	-27.79M
Net Change in Cash	-	-	-101.16M	19.48M	16.18M	-16.10M
Share Buybacks	-	0	9.00M	1.02M	0	-

Ratios (Annual)

Figures in %.

Metric	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	20.6%	18.4%	13.7%	15.2%
Operating Margin %	-4.4%	-	-28.5%	-18.6%	-15.3%	-7.2%
Net Margin %	-7.6%	-	0.1%	-25.6%	-16.4%	-12.1%
ROE %	-51.0%	-	0.1%	-145.7%	-1,801.7%	385.5%
ROCE %	-22.1%	-	-31.0%	-34.5%	-49.9%	-38.5%

Shareholding Pattern

Insiders

18.16%

Institutions

46.09%

Public Float

56.31%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	4.42%	4.42M	$20.71M
2	Vanguard Capital Management LLC	3.48%	3.48M	$16.31M
3	Deerfield Management Company, L.P	3.36%	3.36M	$15.76M
4	Kanen Wealth Management LLC	2.78%	2.78M	$13.03M
5	Josh Arnold Investment Consultant, Llc	2.46%	2.46M	$11.56M
6	Balyasny Asset Management LP	1.83%	1.83M	$8.57M
7	Geode Capital Management, LLC	1.76%	1.76M	$8.24M
8	Wexford Capital LP	1.71%	1.71M	$8.03M
9	CenterBook Partners LP	1.57%	1.57M	$7.36M
10	State Street Corporation	1.46%	1.46M	$6.85M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for TOI

No recent headlines available.

TOI · Healthcare